X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
baricitinib (121) 121
rheumatoid arthritis (65) 65
tofacitinib (59) 59
index medicus (58) 58
rheumatology (42) 42
humans (32) 32
methotrexate (32) 32
inadequate response (31) 31
safety (29) 29
jak inhibitors (25) 25
janus kinase (25) 25
efficacy (24) 24
pharmacology & pharmacy (22) 22
arthritis, rheumatoid - drug therapy (18) 18
placebo (18) 18
double-blind (17) 17
janus kinase inhibitor (17) 17
adalimumab (16) 16
patients (16) 16
ruxolitinib (16) 16
antirheumatic agents - therapeutic use (15) 15
arthritis (15) 15
alopecia areata (14) 14
clinical trials (14) 14
jak inhibitor (14) 14
combination (13) 13
male (13) 13
rheumatoid-arthritis (13) 13
therapy (13) 13
dermatology (12) 12
female (12) 12
adult (11) 11
atopic dermatitis (11) 11
azetidines - therapeutic use (11) 11
middle aged (11) 11
sulfonamides - therapeutic use (11) 11
tumor necrosis factor-tnf (11) 11
analysis (10) 10
disease (10) 10
janus kinases - antagonists & inhibitors (10) 10
modifying antirheumatic drugs (10) 10
protein kinase inhibitors - therapeutic use (10) 10
abridged index medicus (9) 9
aged (9) 9
cytokines (9) 9
drug dosages (9) 9
immunology (9) 9
janus kinase inhibitors (9) 9
medicine & public health (9) 9
psoriasis (9) 9
american-college (8) 8
animals (8) 8
clinical-trials (8) 8
double-blind method (8) 8
dupilumab (8) 8
health risk assessment (8) 8
medicine, general & internal (8) 8
protein kinase inhibitors - adverse effects (8) 8
research (8) 8
rheumatoid factor (8) 8
treatment outcome (8) 8
alopecia (7) 7
antirheumatic agents - adverse effects (7) 7
azetidines - adverse effects (7) 7
care and treatment (7) 7
drugs (7) 7
inflammation (7) 7
methotrexate - therapeutic use (7) 7
recommendations (7) 7
sulfonamides - adverse effects (7) 7
tofacitinib cp-690,550 (7) 7
vitiligo (7) 7
alopecia areata - drug therapy (6) 6
alopecia-areata (6) 6
drug therapy, combination (6) 6
infections (6) 6
jak (6) 6
janus kinase 1 - antagonists & inhibitors (6) 6
japanese patients (6) 6
medical research (6) 6
medicine, experimental (6) 6
mutual fund industry (6) 6
pathogenesis (6) 6
phase-iii (6) 6
preclinical characterization (6) 6
randomized controlled trials as topic (6) 6
studies (6) 6
abatacept (5) 5
active rheumatoid-arthritis (5) 5
antirheumatic agents - administration & dosage (5) 5
apremilast (5) 5
baldness (5) 5
dose-response relationship, drug (5) 5
drug therapy (5) 5
filgotinib (5) 5
herpes zoster (5) 5
interferon (5) 5
internal medicine (5) 5
japan (5) 5
kinases (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of rheumatology, ISSN 0315-162X, 02/2019, Volume 46, Issue 2, pp. 217 - 218
Journal Article
P and T, ISSN 1052-1372, 02/2016, Volume 41, Issue 2, pp. 107 - 114
More than four years after the release of a landmark report by the Institute of Medicine focused attention on pain in America, there are encouraging signs that... 
Journal Article
RHEUMATOLOGY, ISSN 1462-0324, 07/2018, Volume 57, Issue 7, pp. 1131 - 1132
Journal Article
Journal of Rheumatology, ISSN 0315-162X, 01/2018, Volume 45, Issue 1, pp. 14 - 21
Objective. To assess the safety and efficacy of baricitinib in patients with rheumatoid arthritis (RA) up to 128 weeks in a phase IIb study (NCT01185353).... 
Clinical efficacy safety | Phase II | Longterm | Rheumatoid arthritis | Baricitinib | THERAPY | BARICITINIB | SAFETY | LONGTERM | HERPES-ZOSTER | RHEUMATOID ARTHRITIS | CLINICAL EFFICACY | RHEUMATOLOGY | PHASE II
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 04/2019, Volume 80, Issue 4, pp. 913 - 921.e9
Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, modulates proinflammatory cytokine signaling. The efficacy and safety of... 
pruritus | SCORAD | EASI | phase 2 | topical corticosteroids | baricitinib | atopic dermatitis | JAK-STAT signaling | RHEUMATOID-ARTHRITIS | VALIDATION | DERMATOLOGY | TASK-FORCE | DUPILUMAB | TOFACITINIB | Atopic dermatitis | Analysis
Journal Article
Oncotarget, ISSN 1949-2553, 11/2018, Volume 9, Issue 87, pp. 35721 - 35722
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 07/2019, Volume 322, Issue 4, pp. 309 - 311
Journal Article
Regulatory Toxicology and Pharmacology, ISSN 0273-2300, 02/2018, Volume 92, pp. 458 - 471
Baricitinib is a potent and selective Janus kinase (JAK)1 and JAK2 inhibitor, and is approved for the treatment of moderately to severely active RA in adults... 
Rats | Tg.rasH2 mice | Carcinogenicity | Baricitinib | Janus kinase inhibitor
Journal Article
Rheumatology (United Kingdom), ISSN 1462-0324, 09/2016, Volume 55, Issue 9, pp. 1531 - 1533
Journal Article
Modern Rheumatology, ISSN 1439-7595, 2019, pp. 1 - 8
OBJECTIVESBaricitinib is a selective oral inhibitor of JAK1/JAK2 for patients with moderately-to-severely active rheumatoid arthritis (RA). Baricitinib's... 
Janus kinase (JAK) | Japanese | rheumatoid arthritis | safety | Baricitinib
Journal Article
Cytokine, ISSN 1043-4666, 01/2020, Volume 125, p. 154799
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and internal organs. Its pathogenesis, which is still poorly understood,... 
Systemic sclerosis | Fibrosis | IL-4 | IL-13 | Dupilumab | Type 2 immune response | Baricitinib | JAK inhibitors
Journal Article
Journal of Rheumatology, ISSN 0315-162X, 01/2019, Volume 46, Issue 1, pp. 7 - 18
Objective. Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis... 
Safety | Clinical Trials | Rheumatoid arthritis | Baricitinib | Janus kinase inhibitor | BARICITINIB | EFFICACY | SAFETY | CLINICAL TRIALS | INADEQUATE RESPONSE | TUBERCULOSIS | OPPORTUNISTIC INFECTIONS | RISK | OPEN-LABEL | RHEUMATOLOGY | RECOMMENDATIONS | JANUS KINASE INHIBITOR | LONG-TERM SAFETY | CLINICAL-TRIALS | RHEUMATOID ARTHRITIS | TOFACITINIB
Journal Article
Aktuelle Rheumatologie, ISSN 0341-051X, 04/2018, Volume 43, Issue 2, pp. 161 - 168
Zusammenfassung Nachdem in mehreren Phase-III-Studien die Wirksamkeit und Sicherheit gezeigt werden konnte, erhielten Anfang dieses Jahres die ersten beiden... 
Übersichtsarbeit | baricitinib | ustekinumab | apremilast | secukinumab | tofacitinib
Journal Article
ARTHRITIS & RHEUMATOLOGY, ISSN 2326-5191, 06/2017, Volume 69, Issue 6, pp. 1131 - 1134
Journal Article
Arzneimitteltherapie, ISSN 0723-6913, 07/2018, Volume 36, Issue 7-8, pp. 248 - 253
Journal Article
SCIENCE TRANSLATIONAL MEDICINE, ISSN 1946-6234, 09/2019, Volume 11, Issue 511, p. eaav7561
Lichen planus (LP) is a chronic debilitating inflammatory disease of unknown etiology affecting the skin, nails, and mucosa with no current FDA-approved... 
MHC CLASS-I | MEDICINE, RESEARCH & EXPERIMENTAL | APOPTOSIS | INTERFERON-GAMMA | BARICITINIB | INFLAMMATION | DISEASE | CD4(+) | DEATH | INHIBITOR | EXPRESSION | CELL BIOLOGY
Journal Article
Australian prescriber, ISSN 0312-8008, 02/2019, Volume 42, Issue 1, pp. 34 - 35
Journal Article
JOURNAL OF RHEUMATOLOGY, ISSN 0315-162X, 08/2019, Volume 46, Issue 8, pp. 887 - 895
Objective. Magnetic resonance imaging (MRI) was used in a phase IIb study of baricitinib in patients with RA to support dose selection for the phase III... 
JAK INHIBITORS | SCORE | BARICITINIB | INADEQUATE RESPONSE | JOINT DAMAGE | METHOTREXATE | RHEUMATOLOGY | OSTEITIS | SYNOVITIS | MAGNETIC RESONANCE IMAGING | CLINICAL-TRIALS | RHEUMATOID ARTHRITIS | PROGRESSION
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2018, Volume 104, Issue 2, pp. 364 - 373
Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients... 
RHEUMATOID-ARTHRITIS | PATHWAYS | EFFICACY | GM-CSF | SAFETY | DISEASE | PROTEASOME SUBUNIT | LIPODYSTROPHY | PHARMACOLOGY & PHARMACY | ANAKINRA | I INTERFERONOPATHIES | CANDLE | Baricitinib pharmacokinetics | monogenic interferonopathies | compassionate use treatment program | SAVI
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.